Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
15.18
-0.15 (-0.98%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Takeda Pharmaceutical Employees
Takeda Pharmaceutical Company had 49,281 employees as of March 31, 2024. The number of employees increased by 186 or 0.38% compared to the previous year.
Employees
49,281
Change (1Y)
186
Growth (1Y)
0.38%
Revenue / Employee
$590,997
Profits / Employee
$26,854
Market Cap
46.38B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 49,281 | 186 | 0.38% |
Mar 31, 2023 | 49,095 | 1,748 | 3.69% |
Mar 31, 2022 | 47,347 | 248 | 0.53% |
Mar 31, 2021 | 47,099 | -396 | -0.83% |
Mar 31, 2020 | 47,495 | -2,083 | -4.20% |
Mar 31, 2019 | 49,578 | 22,348 | 82.07% |
Mar 31, 2018 | 27,230 | -2,670 | -8.93% |
Mar 31, 2017 | 29,900 | -1,268 | -4.07% |
Mar 31, 2016 | 31,168 | -160 | -0.51% |
Mar 31, 2015 | 31,328 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
TAK News
- 16 days ago - BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3 - Accesswire
- 22 days ago - Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns - Seeking Alpha
- 6 weeks ago - Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds - Seeking Alpha
- 7 weeks ago - Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera - Business Wire
- 2 months ago - The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE) - PRNewsWire
- 2 months ago - Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued - Seeking Alpha
- 2 months ago - Takeda Pharmaceutical Company Limited (TAK) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Suffolk Celebrates Topping off for a Game-Changing New Takeda Facility in Kendall Square Where Science, Art and Community Will Converge - Business Wire